# Analogical Transfer (AT) Pattern Test

**Test Problem**: "How should we handle AI ethics? (novel problem)"
**Test Requirements**: BRIDGE framework, find analogies, cross-domain mapping works

---

## B - Base Problem Articulation

### Concrete Statement
A technology company developing AI systems needs to establish ethical guidelines and governance structures to ensure their AI products are beneficial, fair, and safe while maintaining innovation velocity and competitive position.

### Abstract Structure

**Entities**:
- AI systems (the technology being governed)
- Developers/engineers (creators)
- Company/organization (deployer)
- Users (direct beneficiaries/affected parties)
- Society (indirect affected parties)
- Regulators (potential external governors)
- Competitors (market pressure)

**Relationships**:
- Developers create AI for company
- Company deploys AI to users
- AI affects users directly and society indirectly
- Society provides legitimacy (or withdraws it)
- Regulators can constrain all parties
- Competitors create pressure to move fast

**Constraints**:
- AI behavior is difficult to predict fully
- Consequences may be delayed or hidden
- Power asymmetry (developers/companies vs affected parties)
- Innovation pressure vs caution tension
- Global reach vs local regulations
- Rapidly evolving technology vs slow governance

**Goals**:
- Maximize benefit from AI
- Minimize harm from AI
- Maintain public trust
- Enable innovation
- Ensure fairness across groups

**Tensions**:
- Speed vs Safety
- Innovation vs Precaution
- Profit vs Public Good
- Local Action vs Global Impact
- Expert Knowledge vs Democratic Accountability

### Core Challenge (Domain-Neutral)
*"How does an organization developing powerful new technology with uncertain long-term effects govern its creation and deployment to balance benefit, harm prevention, innovation, and public trust?"*

---

## R - Retrieve Analogous Domains

### Candidate Analogies

| Domain | How It Faces Similar Challenge |
|--------|-------------------------------|
| 1. Pharmaceutical Industry | Powerful products with potential harms; FDA approval process |
| 2. Nuclear Energy/Weapons | Dual-use technology; international governance |
| 3. Medical Ethics / IRBs | Governing research with human subjects |
| 4. Financial Regulation | Complex systems with systemic risk; SEC/banking regulators |
| 5. Environmental Protection | Externalities, long-term effects, tragedy of commons |
| 6. Aviation Safety | High-stakes technology; FAA, incident investigation |
| 7. Professional Licensing (Medicine, Law) | Expert practitioners with power over others |
| 8. Academic Peer Review | Expert knowledge, quality control, reproducibility |
| 9. Food Safety (FDA, USDA) | Consumer protection, supply chain complexity |
| 10. Automotive Safety (NHTSA) | Mass-market technology with safety implications |

---

## I - Investigate Analogies Deeply

### Analogy 1: Pharmaceutical Industry

#### Structural Mapping

| AI Context | Pharmaceutical Context |
|------------|------------------------|
| AI system | Drug |
| AI developers | Drug researchers |
| AI company | Pharmaceutical company |
| Users | Patients |
| Society | Public health |
| Regulators | FDA |
| Deployment | Drug approval & prescription |
| AI failure | Adverse drug reaction |
| AI bias | Drug not working for subpopulations |

#### How Source Domain Solves It

**Pre-market Approval (Phase 1-3 Trials)**:
- Phase 1: Small group, basic safety
- Phase 2: Larger group, efficacy and side effects
- Phase 3: Large-scale, statistically significant
- Regulatory review before market

**Post-market Surveillance**:
- Adverse event reporting (FAERS)
- Ability to recall drugs
- Ongoing monitoring

**Independent Review**:
- FDA as external reviewer
- IRBs for human subjects research
- Published trials for peer scrutiny

#### Key Mechanisms
1. Staged deployment with increasing scale
2. External independent review before deployment
3. Mandatory adverse event reporting
4. Ability to recall/withdraw
5. Clear liability framework

#### Why It Works in Source Domain
- Single-use, discrete products (a drug is testable)
- Well-defined endpoints (efficacy, safety metrics)
- Long history of regulation (trust established)
- Clear harm (patient injury)

#### Mapping Confidence
- **Strong Parallels**: Pre-deployment testing, adverse event reporting, staged rollout
- **Weak Parallels**: AI systems evolve continuously (unlike fixed drug formula); AI harms are often diffuse
- **Unmapped Elements**: AI emergent behavior; continuous learning systems

---

### Analogy 2: Aviation Safety (FAA Model)

#### Structural Mapping

| AI Context | Aviation Context |
|------------|------------------|
| AI system | Aircraft |
| AI developers | Aircraft manufacturers |
| AI company | Airline/operator |
| AI deployment | Flight operations |
| AI failure | Crash/incident |
| Society | Passengers, ground safety |
| Regulators | FAA, NTSB |
| Training data | Component suppliers |

#### How Source Domain Solves It

**Certification Process**:
- Type certification for new aircraft designs
- Extensive testing before commercial use
- Documented safety case

**Safety Culture**:
- Just culture (no-blame reporting)
- Mandatory incident reporting
- NTSB independent investigation
- Industry-wide learning from accidents

**Operational Standards**:
- Pilot training and licensing
- Maintenance requirements
- Operational limits documented

**Redundancy and Fail-safes**:
- Multiple backup systems
- Human override capability
- Degraded mode operations

#### Key Mechanisms
1. Certification before deployment
2. Just culture enabling honest reporting
3. Independent accident investigation with public findings
4. Industry-wide sharing of safety learnings
5. Clear separation of manufacturer, operator, regulator

#### Why It Works in Source Domain
- High stakes create motivation for safety
- Relatively contained failures (crashes are visible)
- Long regulatory history (trust earned)
- Physical systems with predictable failure modes

#### Mapping Confidence
- **Strong Parallels**: Certification, independent investigation, safety culture
- **Weak Parallels**: AI failures are often subtle (bias, not crashes); AI deployed in millions of instances vs individual aircraft
- **Unmapped Elements**: AI evolves continuously; no clear "crash" equivalent for slow harms

---

### Analogy 3: Medical Ethics / Institutional Review Boards (IRBs)

#### Structural Mapping

| AI Context | Medical Research Context |
|------------|-------------------------|
| AI development | Medical research |
| AI developers | Researchers |
| AI subjects (training data) | Human subjects |
| AI deployment | Clinical translation |
| Potential harm | Subject harm |
| Ethics committee | IRB |
| Informed consent | Data consent |

#### How Source Domain Solves It

**IRB Review Process**:
- Independent ethics review before research begins
- Assessment of risk/benefit ratio
- Vulnerable population protections
- Informed consent requirements

**Ongoing Oversight**:
- Progress reports to IRB
- Adverse event reporting
- Ability to halt studies
- Data safety monitoring boards for trials

**Ethical Principles (Belmont Report)**:
- Respect for persons (autonomy, consent)
- Beneficence (maximize benefit, minimize harm)
- Justice (fair distribution of burdens and benefits)

#### Key Mechanisms
1. Prospective ethical review (before, not after)
2. Independent committee (not self-governance)
3. Explicit ethical principles (Belmont Report)
4. Vulnerable population protections
5. Ongoing oversight with halt authority

#### Why It Works in Source Domain
- Clear subject (human participant)
- Defined protocol (testable)
- Established principles (Nuremberg, Belmont)
- Institutional incentives aligned (grants require IRB)

#### Mapping Confidence
- **Strong Parallels**: Prospective review, independent committee, ethical principles
- **Weak Parallels**: AI "subjects" unclear (training data from many people); AI harm more diffuse
- **Unmapped Elements**: Continuous learning; emergent behavior; scale of deployment

---

## D - Distill Transferable Principles

### From Pharmaceutical Industry:

**Principle 1: Staged Deployment with Increasing Scale**
- **Mechanism**: Limit initial exposure; expand only when safety demonstrated
- **Transfer Conditions**: Works when AI can be deployed incrementally
- **Transfer Risks**: AI systems often deployed at scale immediately (internet products)

**Principle 2: Post-Deployment Surveillance and Reporting**
- **Mechanism**: Mandatory adverse event reporting enables early signal detection
- **Transfer Conditions**: Clear definition of "adverse event" for AI
- **Transfer Risks**: AI harms may be diffuse, slow, or contested

**Principle 3: Independent Pre-Deployment Review**
- **Mechanism**: External body reviews before market access
- **Transfer Conditions**: Viable if reviewers have expertise and authority
- **Transfer Risks**: AI evolves quickly; review could bottleneck innovation

---

### From Aviation Safety:

**Principle 4: Just Culture and No-Blame Reporting**
- **Mechanism**: Engineers report problems without fear; organization learns
- **Transfer Conditions**: Applies directly to AI organizations internally
- **Transfer Risks**: External competitive pressure may discourage disclosure

**Principle 5: Independent Incident Investigation with Public Findings**
- **Mechanism**: NTSB-style investigation of major failures; findings published
- **Transfer Conditions**: Requires agreed definition of "major AI incident"
- **Transfer Risks**: Companies may resist public disclosure; competitive information

**Principle 6: Human Override and Degraded Mode**
- **Mechanism**: Humans can always override; systems degrade safely
- **Transfer Conditions**: AI systems designed with human-in-loop
- **Transfer Risks**: Some AI contexts don't allow override (split-second decisions)

---

### From Medical Ethics / IRBs:

**Principle 7: Prospective Ethics Review (Before Development)**
- **Mechanism**: Independent committee reviews ethics before work begins
- **Transfer Conditions**: Establish AI IRB equivalent
- **Transfer Risks**: Scalability for thousands of AI projects; expertise availability

**Principle 8: Explicit Foundational Ethical Principles**
- **Mechanism**: Belmont Report provides clear, agreed ethical foundations
- **Transfer Conditions**: AI needs equivalent consensus ethical framework
- **Transfer Risks**: Less consensus on AI ethics than medical ethics

**Principle 9: Vulnerable Population Protections**
- **Mechanism**: Extra scrutiny for research affecting children, prisoners, etc.
- **Transfer Conditions**: Identify AI-vulnerable populations (low digital literacy, marginalized groups)
- **Transfer Risks**: AI affects everyone; everyone could be "vulnerable"

---

## G - Generate Candidate Solutions

### Solution 1: AI Safety Board (Aviation Model)

**Principle Applied**: Independent incident investigation (from Aviation)

**Implementation**:
- Establish "AI Safety Board" modeled on NTSB
- Investigate significant AI incidents (discrimination, harm, failures)
- Publish findings with recommendations
- Industry-wide sharing of learnings
- No-blame reporting culture internally

**Adaptation Required**:
- Define "AI incident" threshold (impact magnitude, harm type)
- Cross-border coordination (AI is global, NTSB is national)
- Fund through industry consortium or government

---

### Solution 2: Staged AI Deployment (Pharmaceutical Model)

**Principle Applied**: Phased rollout with increasing scale

**Implementation**:
- Phase 1: Internal testing (small scale, controlled)
- Phase 2: Limited beta (invite-only, monitored)
- Phase 3: Gradual rollout with monitoring
- Phase 4: General availability with surveillance
- Required safety case at each stage transition

**Adaptation Required**:
- Define phase criteria for AI (unlike discrete drug trials)
- Continuous integration means phases may blend
- Metrics for "safety demonstrated" in AI context

---

### Solution 3: AI Ethics Review Board (IRB Model)

**Principle Applied**: Prospective independent ethics review

**Implementation**:
- Internal AI Ethics Board reviews high-risk projects before development
- External advisors for independence
- Assessment against published ethical principles
- Ongoing review, not just at launch
- Halt authority for serious concerns

**Adaptation Required**:
- Establish AI-specific ethical principles (like Belmont Report)
- Scale: can't review every ML model; need risk-based triage
- Expertise: board needs technical and ethical competence

---

### Solution 4: Hybrid Governance Framework (Combining Multiple)

**Principles Applied**: Staged deployment + Ethics review + Just culture + Surveillance

**Implementation**:
1. **Pre-development**: AI Ethics Review for high-risk applications
2. **Development**: Just culture encouraging internal reporting of concerns
3. **Pre-deployment**: Staged rollout with safety gates
4. **Post-deployment**: Adverse impact surveillance and reporting
5. **Incident**: AI Safety Board investigation for major events
6. **Industry**: Published learnings and best practices

**Adaptation Required**:
- Define "high-risk" criteria
- Establish foundational AI ethics principles
- Create reporting infrastructure
- Coordinate across companies (industry consortium)

---

## E - Evaluate and Adapt

### Solution 4: Hybrid Governance Framework (Best Candidate)

**Structural Fit**: High
- Addresses full lifecycle (pre-development to post-incident)
- Multiple mechanisms for different failure modes
- Combines internal and external oversight

**Constraint Compatibility**: Medium-High
- Stages can accommodate AI's iterative nature
- Ethics review scaled by risk level
- Reporting infrastructure is feasible

**Side Effects**:
- Innovation slowdown if process too heavy
- False sense of security if implemented superficially
- Liability ambiguity (who's responsible?)

**Implementation**:
- Moderate complexity
- Requires industry coordination for safety board
- Ethics board can be internal initially

**Cultural Fit**: Medium
- Tech industry resistant to external oversight
- Just culture may clash with competitive secrecy
- Startups may lack resources for full framework

### Disanalogies

**Where pharmaceutical analogy breaks down**:
- AI systems evolve continuously (no fixed "formula")
- AI deployed at massive scale instantly (not individual prescriptions)
- Harms often diffuse and delayed (not immediate adverse reaction)

**Where aviation analogy breaks down**:
- AI failures often invisible (bias, not crash)
- No clear "crash" equivalent for many AI harms
- AI deployed in millions of contexts (not individual aircraft)

**Where IRB analogy breaks down**:
- AI "subjects" are often training data, not active participants
- Scale: millions of AI applications vs discrete research studies
- Consent models don't translate directly

### Adaptation for AI Context

1. **Define AI-specific harm categories**: Bias, discrimination, misinformation, manipulation, safety (not just physical harm)
2. **Risk-tiered review**: Light review for low-risk AI, full review for high-risk
3. **Continuous monitoring**: Not just point-in-time approval
4. **Global coordination**: AI is cross-border; governance must be too
5. **Technical auditing**: External auditors who can examine AI systems

---

## Output Summary

# Analogical Analysis: AI Ethics Governance

## Problem Abstraction
"How does an organization developing powerful new technology with uncertain long-term effects govern its creation and deployment to balance benefit, harm prevention, innovation, and public trust?"

## Analogies Investigated

1. **Pharmaceutical Industry** (FDA model)
   - Key Insight: Staged deployment with mandatory adverse event reporting
   - Mapping Strength: Medium (AI evolves; drugs don't)

2. **Aviation Safety** (FAA/NTSB model)
   - Key Insight: Just culture, independent investigation, industry-wide learning
   - Mapping Strength: Medium-High (incident investigation transfers well)

3. **Medical Ethics / IRBs**
   - Key Insight: Prospective ethics review with foundational principles
   - Mapping Strength: Medium (scale challenges; AI "subjects" unclear)

## Transferable Principles

| # | Principle | Source | Transfer Confidence |
|---|-----------|--------|---------------------|
| 1 | Staged deployment | Pharma | 70% |
| 2 | Post-deployment surveillance | Pharma | 80% |
| 3 | Independent pre-deployment review | Pharma | 65% |
| 4 | Just culture | Aviation | 85% |
| 5 | Independent incident investigation | Aviation | 75% |
| 6 | Human override capability | Aviation | 60% |
| 7 | Prospective ethics review | IRB | 70% |
| 8 | Foundational ethical principles | IRB | 80% |
| 9 | Vulnerable population protections | IRB | 75% |

## Proposed Solution: Hybrid Governance Framework

**Combining**: Staged deployment (Pharma) + Ethics review (IRB) + Just culture (Aviation) + Incident investigation (Aviation)

**Five Pillars**:
1. Pre-development ethics review (high-risk projects)
2. Just culture for internal concern reporting
3. Staged rollout with safety gates
4. Adverse impact surveillance and reporting
5. Independent incident investigation for major events

**AI-Specific Adaptations**:
- Risk-tiered review (not all AI needs full review)
- Continuous monitoring (not just point-in-time)
- AI-specific harm categories
- Global coordination mechanisms
- Technical auditing capability

## Disanalogies and Risks

- AI evolves continuously (unlike fixed drugs or aircraft designs)
- AI harms often diffuse and delayed (not crash-like)
- Massive deployment scale challenges staged approaches
- Tech culture resistant to external oversight
- Consent models don't translate directly

## Recommendation

Adopt the Hybrid Governance Framework with phased implementation:

1. **Immediate**: Establish internal AI Ethics Board (IRB model)
2. **6 months**: Implement just culture and internal reporting
3. **12 months**: Join/establish industry AI Safety Board consortium
4. **18 months**: Formalize staged deployment gates
5. **Ongoing**: Develop AI-specific foundational principles (Belmont equivalent)

## Confidence: 75%

**Justification**:
- Three strong analogies investigated with structural mapping
- Multiple principles transfer with good confidence
- Disanalogies identified and adaptations proposed
- Remaining uncertainty: novel aspects of AI not fully captured by any analogy

---

## Test Evaluation

### Methodology Verification

| Criterion | Expected | Actual | Pass/Fail |
|-----------|----------|--------|-----------|
| Base problem abstraction | Domain-neutral | "Powerful technology with uncertain effects" | PASS |
| 5+ candidate analogies | Diverse domains | 10 candidates across regulation, safety, ethics | PASS |
| Top 3 deep investigation | BRIDGE structural mapping | 3 analogies with full mapping tables | PASS |
| Transferable principles | With conditions and risks | 9 principles with transfer confidence | PASS |
| Candidate solutions | From principles | 4 solutions generated | PASS |
| Evaluation with disanalogies | Explicit failure points | All 3 analogies have disanalogies documented | PASS |
| Adaptation to target | AI-specific modifications | 5 AI-specific adaptations listed | PASS |

### Gaps Identified

1. **Enhancement**: Could add more quantitative mapping confidence scores (e.g., percentage for each mapping element, not just overall).

2. **Minor Gap**: The distinction between "strong parallel" and "weak parallel" could be more precise with specific criteria.

3. **Strength**: The BRIDGE framework effectively structured the cross-domain transfer, and the hybrid solution combines insights from multiple analogies.

### Output Quality

- Abstract problem formulation enables cross-domain search
- 10 candidate analogies show broad exploration
- 3 deep investigations with structural mapping tables
- 9 transferable principles with conditions
- Clear disanalogies prevent over-application of analogies
- Actionable phased implementation recommendation

### Test Result: **PASS**

The AT methodology works as documented. BRIDGE framework effectively structures analogical reasoning from problem abstraction through solution generation. Cross-domain mapping worked for a genuinely novel problem (AI ethics), and the disanalogy checks prevented naive transfer of inapplicable mechanisms.
